DDInter281 DDInter875
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Canakinumab may lead to a major life threatening interaction when taken with Natalizumab
Canakinumab may lead to a major life threatening interaction when taken with Satralizumab